Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Toripalimab is an investigational new drug currently being evaluated by the FDA for commercial distribution in the United States.

Immuno-oncology Begins Here

Developing immuno-oncology therapies for patients in need

The successful development of immuno-oncology medicines has significantly improved the prognosis for many people with cancer.

We are building an immuno-oncology franchise, starting with toripalimab, a differentiated PD-1 inhibitor. We plan to add PD-1 combination therapies, including our clinical-stage anti-TIGIT antibody plus internal preclinical programs.

About Coherus Immuno-oncology

Dedicated to Improving Patient Lives by Expanding Access to Life-Changing Biologic Medicines

Our approved products span multiple therapeutic areas including oncology, immunology and ophthalmology.

See our Products & Pipeline

Latest News

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Onc